<DOC>
	<DOCNO>NCT02393924</DOCNO>
	<brief_summary>This study observe different anti-cancer treatment regimens sequence throughout course disease patient unresectable locally advanced ( LA ) metastatic breast cancer ( mBC ) describe clinical outcome treatment regimen measure progression-free survival ( PFS ) .</brief_summary>
	<brief_title>ESTHER : Her2-Positive Unresectable Locally Advanced Metastatic Breast Cancer Disease Registry Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Initially diagnose HER2positive unresectable LA/mBC 6 month prior enrolment , although received anticancer treatment time Age 18 year old There exclusion criterion entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>